Should a patient continue a direct‑acting oral anticoagulant (DOAC) after transcatheter aortic valve implantation (TAVI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Should You Continue a DOAC After TAVI?

If you have an established indication for oral anticoagulation (such as atrial fibrillation), you should continue your DOAC after TAVI—this is the standard of care. If you do not have another indication for anticoagulation, you should take aspirin alone after TAVI, not a DOAC.

For Patients WITH an Indication for Anticoagulation

Continue Your DOAC Long-Term

For patients with bioprosthetic TAVI who have atrial fibrillation or another established indication for anticoagulation, continuing a DOAC at the therapeutic dose for stroke prevention is recommended 1. The 2020 ACC/AHA Valvular Heart Disease Guidelines clearly state that aspirin 75-100 mg daily is reasonable for bioprosthetic TAVI only in the absence of other indications for oral anticoagulants 1.

DOAC vs. Warfarin: DOACs Are Preferred

When you have a choice between a DOAC and warfarin (VKA) after TAVI:

  • DOACs appear to offer better outcomes than warfarin, particularly for reducing cardiovascular death and net adverse clinical events 2, 3, 4
  • A 2026 meta-analysis found DOACs reduced the risk of net adverse clinical events (RR: 0.84) and cardiovascular death (RR: 0.78) compared to warfarin 2
  • The German GARY registry (45,598 TAVI patients) showed similar all-cause mortality and cardiac/cerebrovascular events between DOACs and warfarin, supporting DOAC use as at least equivalent 3
  • DOACs may carry a slightly higher bleeding risk, particularly when combined with antiplatelet therapy, but this must be weighed against their mortality benefit 2

Periprocedural Management: Continue or Interrupt?

The question of whether to continue or temporarily interrupt your DOAC during the TAVI procedure itself is more nuanced:

  • The 2025 POPular PAUSE TAVI trial found that continuation was NOT noninferior to interruption for the composite endpoint of cardiovascular death, stroke, MI, major vascular complications, or major bleeding 5
  • Continuation resulted in significantly more bleeding (31.1% vs 21.3%, risk difference 9.8 percentage points) 5
  • However, thromboembolic events were similar between groups (8.8% vs 8.2%) 5
  • A 2026 meta-analysis suggested continuation may be feasible without increased major bleeding, but acknowledged the evidence is limited and statistically fragile 6

Practical recommendation: Given the increased bleeding risk without clear thromboembolic benefit, interruption of your DOAC for the TAVI procedure appears safer, with resumption shortly after hemostasis is achieved. This aligns with the high-bleed-risk classification of TAVI procedures 7.

Avoid Combining DOAC with Dual Antiplatelet Therapy

Do not use rivaroxaban 10 mg daily plus aspirin after TAVI—this combination is contraindicated 1. The GALILEO trial showed harm with this regimen. If you need antiplatelet therapy for coronary disease in addition to your DOAC:

  • Aspirin should be discontinued after 1-4 weeks of triple therapy 8
  • Continue DOAC plus clopidogrel (not aspirin) to reduce bleeding risk 8
  • After 6-12 months, transition to DOAC alone 8

For Patients WITHOUT an Indication for Anticoagulation

Single antiplatelet therapy with aspirin 75-100 mg daily is the standard recommendation 1, 9. The evidence does not support routine DOAC use in patients without atrial fibrillation or other anticoagulation indications:

  • Dual antiplatelet therapy (aspirin plus clopidogrel) for 3-6 months may be reasonable in low-bleeding-risk patients, but this is a weak recommendation 1
  • Recent trials (POPULAR-TAVI, ENVISAGE-TAVI AF) support simplified antiplatelet strategies 9

Key Contraindications

DOACs are absolutely contraindicated if you have a mechanical valve prosthesis 1. This applies to mechanical valves, not bioprosthetic TAVI valves. For mechanical valves, warfarin is required.

Bottom Line Algorithm

  1. Do you have atrial fibrillation, prior VTE, or another indication for anticoagulation?

    • YES: Continue your DOAC long-term after TAVI. Prefer DOAC over warfarin. Consider interrupting (not continuing) your DOAC during the TAVI procedure itself to reduce bleeding risk.
    • NO: Take aspirin 75-100 mg daily. Do not start a DOAC.
  2. Do you also need antiplatelet therapy for coronary disease?

    • Use DOAC plus clopidogrel (not aspirin) for up to 6-12 months, then DOAC alone
    • Never use rivaroxaban 10 mg plus aspirin after TAVI
  3. Do you have a mechanical valve?

    • DOACs are contraindicated—use warfarin instead

References

Research

Continuation versus Interruption of Oral Anticoagulation during TAVI.

The New England journal of medicine, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.